CU20140060A7 - 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato - Google Patents

4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato

Info

Publication number
CU20140060A7
CU20140060A7 CU2014000060A CU20140060A CU20140060A7 CU 20140060 A7 CU20140060 A7 CU 20140060A7 CU 2014000060 A CU2014000060 A CU 2014000060A CU 20140060 A CU20140060 A CU 20140060A CU 20140060 A7 CU20140060 A7 CU 20140060A7
Authority
CU
Cuba
Prior art keywords
amino
carboxamide
phenyl
monohidrate
trifluorometil
Prior art date
Application number
CU2014000060A
Other languages
English (en)
Inventor
Juergen Stiehl
Werner Heilmann
Michael Lögers
Joachim Rehse
Michael Gottfried
Saskia Wichmann
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20140060(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20140060A7 publication Critical patent/CU20140060A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere al compuesto -{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxiI}-N-metilpiridina-2-carboxamida, sus sales y su monohidrato.
CU2014000060A 2010-04-15 2014-05-26 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato CU20140060A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15
PCT/EP2011/055508 WO2011128261A1 (en) 2010-04-15 2011-04-08 Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate

Publications (1)

Publication Number Publication Date
CU20140060A7 true CU20140060A7 (es) 2014-10-02

Family

ID=44070712

Family Applications (2)

Application Number Title Priority Date Filing Date
CU20120147A CU24123B1 (es) 2010-04-15 2011-04-08 Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato
CU2014000060A CU20140060A7 (es) 2010-04-15 2014-05-26 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CU20120147A CU24123B1 (es) 2010-04-15 2011-04-08 Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato

Country Status (39)

Country Link
US (5) US8748622B2 (es)
EP (1) EP2558448B1 (es)
JP (1) JP5934182B2 (es)
KR (2) KR20170129276A (es)
CN (2) CN103980191A (es)
AR (2) AR081060A1 (es)
AU (1) AU2011240113B2 (es)
BR (1) BR112012026117B1 (es)
CA (1) CA2796238C (es)
CL (1) CL2012002840A1 (es)
CO (1) CO6630136A2 (es)
CR (1) CR20120526A (es)
CU (2) CU24123B1 (es)
DK (1) DK2558448T3 (es)
DO (2) DOP2012000268A (es)
EC (1) ECSP12012234A (es)
ES (1) ES2542610T3 (es)
GT (1) GT201200280A (es)
HK (1) HK1200831A1 (es)
HR (1) HRP20150885T1 (es)
HU (1) HUE026821T2 (es)
IL (2) IL222348B (es)
JO (1) JO3158B1 (es)
MA (1) MA34156B1 (es)
MX (1) MX2012011734A (es)
MY (2) MY177066A (es)
NZ (1) NZ602997A (es)
PE (2) PE20130181A1 (es)
PL (1) PL2558448T3 (es)
PT (1) PT2558448E (es)
RS (1) RS54219B1 (es)
RU (1) RU2581585C2 (es)
SG (2) SG10201501221UA (es)
SI (1) SI2558448T1 (es)
TN (1) TN2012000492A1 (es)
TW (2) TWI539951B (es)
UA (1) UA110613C2 (es)
UY (2) UY33290A (es)
WO (1) WO2011128261A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91520C2 (en) * 2004-09-29 2010-08-10 Баер Шеринг Фарма Акциенгезельшафт Thermodynamically stable form of tosylate
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35006A (es) 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
CA2885688C (en) 2012-09-25 2021-03-02 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating cancer
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
WO2015049698A2 (en) * 2013-10-04 2015-04-09 Hetero Research Foundation Process for regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
US9790185B2 (en) 2014-07-09 2017-10-17 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
US20190300484A1 (en) * 2016-01-18 2019-10-03 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
PL3630112T3 (pl) 2017-06-02 2024-07-01 Bayer Healthcare Llc Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
PT2305255E (pt) 2001-12-03 2012-09-04 Bayer Healthcare Llc Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
DK1580188T3 (da) 2002-02-11 2012-02-06 Bayer Healthcare Llc Forbindelser af arylurea som kinaseinhibitorer
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
ME00294B (me) 2003-07-23 2011-05-10 Bayer Pharmaceuticals Corp Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN101048140B (zh) 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物
UA91520C2 (en) 2004-09-29 2010-08-10 Баер Шеринг Фарма Акциенгезельшафт Thermodynamically stable form of tosylate
SI1797037T1 (sl) 2004-09-29 2015-06-30 Bayer Healthcare Llc Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
JP2009513706A (ja) 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー ソラフェニブを用いた癌の治療
JP2009515978A (ja) 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509253A (ja) * 2006-11-09 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉｉ
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
EP2111401B1 (en) 2006-12-20 2011-02-16 Bayer HealthCare, LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
WO2008089388A2 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
EP2129376B1 (en) 2007-01-19 2013-07-24 Bayer HealthCare LLC Treatment of cancers with acquired resistance to KIT inhibitors
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CA2741087A1 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
RU2011150619A (ru) 2009-05-15 2013-06-20 Новартис Аг Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2013000917A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing regorafenib
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
UY35006A (es) 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib

Also Published As

Publication number Publication date
US20170334857A1 (en) 2017-11-23
MA34156B1 (fr) 2013-04-03
ES2542610T3 (es) 2015-08-07
CA2796238A1 (en) 2011-10-20
KR20130061670A (ko) 2013-06-11
TWI539951B (zh) 2016-07-01
BR112012026117B1 (pt) 2022-08-30
PE20130181A1 (es) 2013-02-23
IL253119B (en) 2018-03-29
US20190144391A1 (en) 2019-05-16
DOP2012000268A (es) 2012-12-15
AR081060A1 (es) 2012-06-06
CL2012002840A1 (es) 2013-01-18
RS54219B1 (en) 2015-12-31
CR20120526A (es) 2013-03-11
IL222348B (en) 2018-08-30
GT201200280A (es) 2014-07-23
US10822305B2 (en) 2020-11-03
BR112012026117A2 (pt) 2015-09-08
CU24123B1 (es) 2015-08-27
NZ602997A (en) 2014-10-31
US20170057918A1 (en) 2017-03-02
TW201509415A (zh) 2015-03-16
US8748622B2 (en) 2014-06-10
AU2011240113A1 (en) 2012-10-11
US9458107B2 (en) 2016-10-04
UY39590A (es) 2022-01-31
PL2558448T3 (pl) 2015-10-30
ECSP12012234A (es) 2012-11-30
KR20170129276A (ko) 2017-11-24
IL253119A0 (en) 2017-08-31
CN102947271B (zh) 2016-11-09
TN2012000492A1 (en) 2014-04-01
BR112012026117A8 (pt) 2017-12-19
HUE026821T2 (en) 2016-07-28
DK2558448T3 (en) 2015-08-24
EP2558448B1 (en) 2015-05-20
HK1200831A1 (en) 2015-08-14
IL222348A0 (en) 2012-12-31
AR116395A2 (es) 2021-05-05
RU2012148386A (ru) 2014-05-20
MY177066A (en) 2020-09-03
RU2581585C2 (ru) 2016-04-20
JO3158B1 (ar) 2017-09-20
DOP2016000285A (es) 2016-11-30
CU20120147A7 (es) 2013-01-30
UA110613C2 (uk) 2016-01-25
CN103980191A (zh) 2014-08-13
KR101800041B1 (ko) 2017-11-21
SG184172A1 (en) 2012-11-29
US20130116442A1 (en) 2013-05-09
TW201204356A (en) 2012-02-01
JP2013523851A (ja) 2013-06-17
PE20160838A1 (es) 2016-09-24
SG10201501221UA (en) 2015-04-29
MY162359A (en) 2017-06-15
CO6630136A2 (es) 2013-03-01
HRP20150885T1 (hr) 2015-10-09
TWI475992B (zh) 2015-03-11
CA2796238C (en) 2019-12-31
AU2011240113B2 (en) 2014-12-18
MX2012011734A (es) 2012-12-17
UY33290A (es) 2011-12-01
US20140221661A1 (en) 2014-08-07
EP2558448A1 (en) 2013-02-20
JP5934182B2 (ja) 2016-06-15
SI2558448T1 (sl) 2015-11-30
WO2011128261A1 (en) 2011-10-20
CN102947271A (zh) 2013-02-27
PT2558448E (pt) 2015-09-01

Similar Documents

Publication Publication Date Title
CU20140060A7 (es) 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato
UA109924C2 (uk) Аміди аміноінданів, які мають високу фунгіцидну активність та їх фітосанітарна композиція
BR112013033511A8 (pt) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)ethóxi)fenil)butil)carbamimidoil) pirazina-2-carboxamida
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
DK3130347T3 (da) PH20-polypeptidvarianter, formuleringer og anvendelser deraf
DK2760444T3 (da) Cannabinoidcarboxylsyrer, salte af cannabinoidcarboxylsyrer, fremstilling og anvendelse deraf
RS54642B1 (en) MEGLUMIN SO 6-FLUOR-3-HYDROXY-2-PYRAZINE CARBOXAMIDE
UY33958A (es) Inhibidores de la glucosilceramida sintasa
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
UA110880C2 (uk) Заміщені амідином бета-лактами, їх одержання та застосування як антибактеріальних засобів
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UA22925S (uk) Переносний інформаційний термінал
EA201390074A1 (ru) 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
EA201490450A1 (ru) Новые ингибиторы ферментов
UY34211A (es) ?métodos y composiciones para producir arroz resistente a inhibidores de accasa?.
UY34442A (es) 2-tiopirimidinonas.
UY4153Q (es) Batería
HN2008001859A (es) Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida.
UY34791A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida
FR2982157B1 (fr) Composition cosmetique ou dermatologique comprenant un alpha-alcoxysilane a base uree ou amide
UA118008C2 (uk) Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
EA201301235A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
IT1399461B1 (it) Ramosa.
UA111156C2 (uk) Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою